home technology applications about us news
Amino Acid Analysis using HPCE - a poster from Analytix 2012 exhibition in Beijing.  deltaDOT’s core technology showing Label Free Intrinsic Imaging (LFII®) applied to indirect  UV measurements, using a UV-absorbing buffer. This allows the transmission of light as the  non-UV-absorbing analytes pass the detector window. Indirect UV can be used in the analysis  of substances inaccessible to the normal CE methodology. (...more)
Amino Acid Analysis poster, Beijing 2012
LFII® in HPCE How it works poster, Beijing 2012 
Label Free Intrinsic Imaging (LFII®) is a methodology of analysis which removes a whole class  of systematic errors associated with labels and stains, using the absorbance characteristics of  the molecule as defined by Beers Law. In proteomics, typically the peptide bond between each  amino acid is detected at 214nm. LFII® has also been applied in the analysis of Peptides and  Amino Acids, of small molecules and in Baculovirus Expression system titres (...more)
We were set up as an Imperial spin-out in November 2000 and rented space in several of the  college’s departments during our first five years. For the past five years we have been based in  the Imperial Incubator on the College’s South Kensington campus. Being based in an  incubator, instead of an academic department, has helped us make the transition into being a  commercial company. Although we are now at LBIC, strong links remain between deltaDOT  and research groups at Imperial that are using our technology (...more) 
LBIC News article Summer 2011 
Biopharmaceutical HPCE Applications poster, Beijing 2012 
deltaDOT’s Label Free Intrinsic Imaging (LFII®) systems enable higher quality separations  than existing CE technologies – allowing direct monitoring of unlabelled biomolecules,  reducing the cost and time per analysis. Advantages of LFII® in Capillary Electrophoresis over  traditional techniques include: Accuracy and Precision / Efficient separation / High resolution /  Rapid analysis / direct oncapillary Quantitation / Economy (...more)
Clinical collaboration with Royal Veterinary College
A Label-Free High Performance Capillary Electrophoresis (HPCE). method developed by  deltaDOT for the determination of Glomerular Filtration Rate (GFR) values in feline subjects  administered with contrast agent Iohexol. This CE technique was found to give quick result  with minimum sample preparation and lower costs as compared with traditional HPLC  (...more) 
24th January 2017 – deltaDOT Ltd. announces compliance with CFR 21 part 11 of USA’s  Food and Drug Administration. deltaDOT now offers an upgraded version of its control and  analysis software which has been designed to aid users of deltaDOT’s HPCE-512 Hig  Performance Capillary Electrophoresis instrument in achieving compliance with CFR 21 part  11.The upgrade package contains controls to help meet the stringent requirements of CFR  21 part 11 including the system access by authorised personel only, maintaining audit trails  of user actions, generating complete and protected data files and the application of  electronic signatures to data (...more)  20 Sep 2016 National Health Service Quality Control North West (QCNW) Liverpool  labs  presented the data on monoclonal antibody stability trials based on deltaDOT’s Capillary  Electrophoresis (CE) technology  and expertise. They state that CE technology is suitable for  monitoring the stability of monoclonal antibodies and can perform purity and charge analysis  with high resolution and repeatability. They conclude that CE can replace other techniques  commonly used for this analysis IEC and SDS PAGE (link to the poster).  3rd July 2016 Monoclonal Antibody Stability Trials using deltaDOT HPCE-512 technology  reported by Dr. Deepika Devanur. Now available in pdf slide format on our website (...more)  4th March 2016, FDA CFR21/11 Compliance - deltaDOT’s progress continues with the  implementation of the software quality system while the P3 controller system management  software and the P3EVA analysis package had their compliance completed previously  deltaDOT engineers are working with Optra systems of California (...more)  26th January 2016, National Health Service Quality Control North West (QCNW) Liverpool  Labs are to perform monoclonal antibody stability trials, utilising deltaDOT Ltd. technology  and expertise to aid the study.     4th February 2016 Webinar: Improve your Monoclonal Antibodies Analysis. Live webinar  on analysing mAbs from production to patient. Given jointly by Horiba Scientific and  deltaDOT Ltd. Presented by Dr. Deepika Devanur (...registration site)  14th December 2015, deltaDOT technology used to define product quality for ImmBio  Ltd. deltaDOT Ltd (London) are pleased to announce that its Label Free Intrinsic Imaging  (LFII®) technology has been used to help ImmBio (Cambridge UK) to submit an  Investigational Medicinal Product Dossier (IMPD) as part of a clinical trial application to The  Medicines and Healthcare products Regulatory AgencMHRA (...more)  24th  November 2015, NW Labs are to market a kidney function test developed by  deltaDOT Ltd and the Royal Veterinary College. At the London Vet Show held at Olympia  on 19 and 20 Nov 2015 it was announced that NW Labs are now promoting deltaDOT’s  Glomerular filtration rate (GFR) assay for measuring kidney function in cats and dogs. NW  Labs will refer cases of suspected early stage renal disease for measurement by deltaDOT  with interpretation and advice on management by expert clinicians at the Royal Veterinary  College, London (...more) 12-14 March 2015, 2nd International Conference on Label-Free Technologies  Boston Marriott Cambridge, MA, USA. Dr. Stuart Hassard will be speaking on Label free  intrinsic imaging high performance capillary electrophoresis - a powerful tool in analytical  science. 4th, 5th March 2015 Keeping pace - Analytics for tomorrow’s biopharmaceuticals    conference, Leeds, UK. Dr. Stuart Hassard will be speaking on Label free intrinsic imaging  high performance capillary electrophoresis trends throughout biopharmaceutical process  analytical technology. 
Quality Control of Glycoproteins
Biopharmaceuticals are of ever increasing importance in the pharma industry, with the current  market share of over 20% expected to rise steadily year after year 1. The efficacy and safety  of protein based pharmaceuticals are influenced not only by primary, secondary and tertiary  structure, but also by various post translational modifications (PTM), with glycosylation being  the most common (...more)